2017 News Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014
DateTitle 
09/18/17Heron Therapeutics to Present at the Cantor Fitzgerald Global Healthcare ConferencePrinter Friendly Version
08/09/17Heron Therapeutics Reports Financial Results for the Three and Six Months Ended June 30, 2017 and Recent Corporate ProgressPrinter Friendly Version
08/09/17Heron Therapeutics Announces Initiation of Phase 3 Program for HTX-011 in Postoperative Pain Following Successful End-of-Phase 2 Meeting with FDAPrinter Friendly Version
05/30/17Heron Therapeutics to Present at the Jefferies 2017 Healthcare ConferencePrinter Friendly Version
05/10/17Heron Therapeutics Reports Financial Results for the Three Months Ended March 31, 2017 and Recent Corporate ProgressPrinter Friendly Version
05/09/17Heron Therapeutics to Present at the Bank of America Merrill Lynch 2017 Healthcare ConferencePrinter Friendly Version
04/24/17Heron Therapeutics Appoints Robert E. Hoffman as Chief Financial Officer and Senior Vice President, FinancePrinter Friendly Version
03/28/17Heron Therapeutics to Present at the 16th Annual Needham Healthcare ConferencePrinter Friendly Version
03/13/17Heron Therapeutics to Present at the Oppenheimer 27th Annual Healthcare ConferencePrinter Friendly Version
02/28/17Heron Therapeutics to Present at the 37th Annual Cowen and Company Healthcare ConferencePrinter Friendly Version
02/24/17Heron Therapeutics Announces Inclusion of SUSTOL® (Granisetron) Extended-Release Injection in NCCN® Antiemesis GuidelinesPrinter Friendly Version
02/23/17Heron Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Recent Corporate ProgressPrinter Friendly Version
02/08/17Heron Therapeutics to Present at the Leerink Partners 6th Annual Global Healthcare ConferencePrinter Friendly Version
01/31/17Heron Therapeutics Announces Underwriters’ Exercise in Full of Option to Purchase Additional SharesPrinter Friendly Version
01/19/17Heron Therapeutics Announces Pricing of Underwritten Public Offering of Common StockPrinter Friendly Version
01/18/17Heron Therapeutics Announces Proposed Public Offering of Common StockPrinter Friendly Version
01/12/17Heron Announces Submission of CINVANTI™ NDA for the Prevention of Chemotherapy-Induced Nausea and Vomiting (CINV)Printer Friendly Version
01/05/17Heron Therapeutics to Present at the 35th Annual J.P. Morgan Healthcare ConferencePrinter Friendly Version
01/04/17Heron Therapeutics Announces Positive Topline Results From Phase 2 Clinical Trial of HTX-011 in AbdominoplastyPrinter Friendly Version
01/04/17Heron Therapeutics Establishes Synergy of Bupivacaine and Meloxicam with HTX-011 for Prevention of Post-Operative Pain in Phase 2 Clinical StudiesPrinter Friendly Version